TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03321981
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: same endocrine therapy is administered as the last line of endocrine therapy
Study: NCT01360645
Drug: Placebo + ADT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + FDA Approved Antidepressant (ADT)
Study: NCT02834117
Drug: moderate ovarian stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
Study: NCT02377752
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered IV
Study: NCT03462017
Drug: SAR247799
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Capsule Route of administration: Oral
Study: NCT03462017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Capsule Route of administration: Oral
Study: NCT03462017
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution Route of administration: Transdermal
Study: NCT01811485
Drug: LMF237 50/250 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily
Study: NCT01811485
Drug: LMF237 50/500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily
Study: NCT01811485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily
Study: NCT01062555
Drug: Prograf & Cellcept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
Study: NCT03516773
Drug: EB612 (EBP05)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entera Bio's proprietary drug for the administration of PTH(1-34) orally
Study: NCT03516773
Drug: NATPARA/NATPAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: A PTH replacement (PTH \[1-84\]; NATPARA (Shire-NPS Pharmaceuticals, Inc., Lexington, Massachusetts) was approved by the United States (US) Food and Drug Administration (FDA) in April 2015 / NATPAR (Shire Pharmaceuticals Ltd., Dublin, Ireland) was approved by the European Medicines Agency in April 2017 for use as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Like many other hormonally active peptides, PTH (1 84); NATPARA is parenterally administered. In this protocol when a specific formulation is referenced (e.g. NATPARA) it may be read interchanged with the alternate formulation (e.g. NATPAR).
Study: NCT02427386
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage of the placebo (alcohol solution) will be of 3 drops, 2 times a day throughout the period of study.
Study: NCT02570724
Drug: injection of HES  Voluven® 
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection into the epidural space of 15 to 30 ml Voluven ® at a rate of 1 ml / about 5 seconds.
Study: NCT01062555
Drug: Rapamune and Cellcept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
Study: NCT03984890
Drug: Traditional treatment of CGD and TB
Normalized name: Betagen brand of Betamethasone and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tuberculosis drugs, interferon-gamma
Study: NCT02018536
Drug: GSK2336805 30 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 1 tablet of 30 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
Study: NCT02018536
Drug: GSK2336805 60 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 2 tablets of 30 mg ie, 60 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
Study: NCT02018536
Drug: GSK2336805 120 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 4 tablets of 30 mg ie, 120 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
Study: NCT02018536
Drug: GSK2336805 60 mg (Treatment B and part of Treatment C and D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
Study: NCT02018536
Drug: TMC435 100 mg (part of Treatment C)
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
Study: NCT02018536
Drug: TMC435 150 mg (part of treatment D)
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
Study: NCT03617536
Drug: CR845 0.25 mg Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR845 0.25 mg medication taken orally 1 time/day
Study: NCT03617536
Drug: CR845 0.5 mg Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR845 0.5 mg medication taken orally 1 time/day
Study: NCT03617536
Drug: CR845 1 mg Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR845 1 mg medication taken orally 1 time/day
Study: NCT03617536
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken orally 1 time/day
Study: NCT01117298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tab Placebo every alternate day for 8 weeks
Study: NCT01555073
Drug: pregabalin/celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.
Study: NCT01555073
Drug: celecoxib/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.
Study: NCT01555073
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group, two placebo tablets day of surgery and twice a day for 13 days
Study: NCT02003794
Drug: 0.9% NaCl solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution intravenous infusion: 100 ml/hr for three days.
Study: NCT01731158
Drug: TKI: Sutent, Nexavar or Votrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: TKI
Study: NCT00000487
Drug: antihypertensive agents
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000487
Drug: diuretics
Normalized name: DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01049204
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 24 weeks
Study: NCT00939029
Drug: placebo NRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo patches (containing no active ingredient)per day for 8 weeks
Study: NCT01496326
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10% ibuprofen cream formulation at a dose of 200mg
Study: NCT01496326
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 grams of placebo cream for 14 days
Study: NCT02091362
Drug: LY2409021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02091362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02662504
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.
Study: NCT03973554
Drug: CPP-ACP
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remineralising sugar free dental topical crème, containing bio-available calcium and phosphate
Study: NCT04589234
Drug: Salmonella-IL2
Normalized name: SALMONELLA ENTERICA ENTERICA SEROVAR ENTERITIDIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2 study to determine the anti-tumor effectiveness of Salmonella-IL2 (Saltikva) with standard of care chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane) for metastatic pancreatic cancer
Study: NCT04589234
Drug: FOLFIRINOX Alone (Historical Controls)
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will use historical data from the literature to compare FOLFIRINOX alone against the FOLFIRINOX with Salmonella-IL2 group
Study: NCT01273441
Drug: PPI, amoxicillin, metronidazole and clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy for 5 days: PPI and 1g amoxicillin every 12h. After dual therapy continue with a triple therapy for 5 days: PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
Study: NCT01273441
Drug: PPI, amoxicillin, metronidazole and clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy for ten days:PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
Study: NCT01887613
Drug: Regnite
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02543073
Drug: Glucocorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.
Study: NCT04181008
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiloride Nasal Spray
Study: NCT03907176
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg
Study: NCT03907176
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg
Study: NCT03907176
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g
Study: NCT02063867
Drug: Arm 2: Decolonization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.
Study: NCT03869385
Drug: Albutein® 200 g/L or Plasbumin® 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of the trial drug must be started within 6 to 24 hours after the beginning of the septic shock. Starting dose: 60 g human albumin 20% (Albutein® 200 g/L, infusion solution) over 2-3 h Daily administration of the trial drug will be based on the serum albumin concentration measured each day. Dose adjustment will follow a predetermined schedule with the aim of maintaining a serum albumin concentration of at least 30 g/l. Administration of the trial drug will continue for a maximum of 28 study days after randomisation and only as long as the participant is being treated in the ICU.
Study: NCT01301066
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin 40 mg QD
Study: NCT02308163
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03669757
Drug: LEO 134310
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
Study: NCT03669757
Drug: LEO 134310 vehicle
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active substance: none
Study: NCT01108731
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take an increasing number of placebo pills for the first 9 days during the ramp up period and then take one pill in the morning and one in the evening for the remaining 8 weeks of the study.
Study: NCT01894048
Drug: Qvar® (beclometasone dipropionate HFA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
Study: NCT00465452
Drug: Continuous Release Dopamine Agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Release Dopamine Agonists
Study: NCT01127672
Drug: corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Under sterile conditions, patients will receive a 4 cc injection consisting of 2 cc Celestone Soluspan (6mg/ml) and 2 cc of 1% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions.
Study: NCT04115982
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: One vial every 15 days during 2 months
Study: NCT04115514
Drug: Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug Administration:~* Dose/Volume- Liothyronine Sodium 50 mcg / 10 mL~* Frequency/Duration: Twice daily over 5 days (10 total doses), or until extubation, whichever comes first.~* Method: Instilled via a catheter through the ETT directly into the airway.
Study: NCT00025064
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00025064
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00566982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)
Study: NCT03017872
Drug: NRTIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined.
Study: NCT01147887
Drug: Drug combination/ 26489112
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 1 and on Day 19, a single, oral dose of a drug combination consisting of midazolam (2 mg/mL liquid), tolbutamide (a 500 mg tablet), and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21, a single oral dose of two 26489112 tablets will be taken.
Study: NCT01814319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral twice daily
Study: NCT00776594
Drug: Androgen Deprivation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: leuprolide: 22.5mg given IM every 3 months for a total of 6 months or, goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months
Study: NCT00788931
Drug: IV LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00788931
Drug: Oral LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02141633
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: participant will be received a 4-week course of identically appearing placebo (2 puffs twice a day via spacer).
Study: NCT00327015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
Study: NCT01470742
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
Study: NCT00005643
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00801723
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablet once daily.
Study: NCT04353375
Drug: HMPL-453
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort_2:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Day 1 to 14\], followed by 7 days off \[Day 15 to 21\], 21 days as a treatment cycle)
Study: NCT00134992
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00921180
Drug: Placebo and peginterferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
Study: NCT04131322
Drug: Amgevita 40Mg Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40Mg Solution for Injection
Study: NCT04131322
Drug: HUMIRA 40Mg Solution for Injection
Normalized name: 0.8 ML Humira 40 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40Mg Solution for Injection
Study: NCT02995161
Drug: BAY987521
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-106)
Study: NCT02995161
Drug: SPF control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study: NCT03122678
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03122678
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00346606
Drug: Denosin® and Xyzal®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00313313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, Daily AM/PM, (24 weeks ST, 12 months LT)
Study: NCT04277663
Drug: IBI310+IBI308
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group, subjects will be given IBI310 3mg/kg IV Q3W in combination with IBI308 200mg IV Q3W for 4 cycles, then follow up a maintenance therapy performed with IBI310 3mg/kg IV Q12W in combination with IBI308 200mg IV Q3W until disease progression or loss of clinical benefit.
Study: NCT04277663
Drug: IBI308
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group, subjects will be given IBI308 200mg IV Q3W until disease progression or loss of clinical benefit
Study: NCT01880294
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asian participants diagnosed with chronic constipation using ANMA diagnostic questionnaire will be observed.
Study: NCT00566150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible dose up to 2500mg per day, for 6 weeks.
Study: NCT04523623
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 10mg/kg, max 800mg, randomized between that and Oxycodone
Study: NCT00851552
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01813058
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to:~1. Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery or~2. TXA as previously described.
Study: NCT00154700
Drug: Paclitaxel,Cisplatin,5-Fu,Folic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01232504
Drug: rhGM-CSF group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
Study: NCT01232504
Drug: rhG-CSF group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
Study: NCT00386750
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04222699
Drug: Mupirocin calcium ointment, 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.
Study: NCT00431444
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00431444
Drug: Placebo oral pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00431444
Drug: Placebo intravenous (i.v.) infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03136497
Drug: 400mg ABT-199
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose daily until disease progression
Study: NCT03136497
Drug: 800mg ABT-199
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose daily until disease progression
Study: NCT03400865
Drug: HCQ/CQ and CAB combined treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.After therapy of 3 months the medication will be stopped if does not reduce prl level more than 20% or failure to decrease prolactinoma size.
Study: NCT00616018
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day for 10 consecutive days
Study: NCT02336685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
Study: NCT02336685
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioids will be administered as standard of care for osteoarthritis (OA) pain therapy during the double-blind treatment phase as per investigator discretion.
Study: NCT02265536
Drug: LY3022855
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01517451
Drug: Androgen Deprivation Therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT.
Study: NCT00096135
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV over 15-30 minutes